{"paper_id":"16b668f0-7cc4-4729-ae81-6a9bc47cca1e","body_text":"eprints@whiterose.ac.uk\nhttps://eprints.whiterose.ac.uk\nUniversities of Leeds, Sheffield and York\nDeposited via The University of Sheffield.\nWhite Rose Research Online URL for this paper:\nhttps://eprints.whiterose.ac.uk/id/eprint/196221/\nVersion: Accepted Version\nArticle:\nYe, L., Whitaker, L.H.R., Mawson, R.L. et al. (2022) Easily missed: endometriosis. British \nMedical Journal (BMJ), 379. e068950. ISSN: 1759-2151 \nhttps://doi.org/10.1136/bmj-2021-068950\nThis article has been accepted for publication in British Medical Journal (BMJ), 2022 \nfollowing peer review, and the Version of Record can be accessed online at \nhttps://doi.org/10.1136/bmj-2021-068950. © Authors (or their employer(s)) 2022. Reuse of \nthis manuscript version (excluding any databases, tables, diagrams, photographs and \nother images or illustrative material included where a another copyright owner is identified)\nis permitted strictly pursuant to the terms of the Creative Commons Attribution-Non \nCommercial 4.0 International (https://creativecommons.org/licenses/by-nc/4.0/)\nReuse \nThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) \nlicence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new \nworks must also acknowledge the authors and be non-commercial. You don’t have to license any derivative \nworks on the same terms. More information and the full terms of the licence here: \nhttps://creativecommons.org/licenses/ \nTakedown \nIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by \nemailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. \n\nConfidential: For Review Only\nEasily Missed: Endometriosis, an update \nJournal: BMJ\nManuscript ID BMJ-2021-068950.R1\nArticle Type: Practice\nDate Submitted by the \nAuthor: 20-Jun-2022\nComplete List of Authors: Ye, Louie; The Royal Women's Hospital, Obstetrics and Gynaecology; \nThe University of Melbourne - Parkville Campus\nWhitaker, Lucy; University of Edinburgh Centre for Reproductive Biology, \nMRC Centre for Reproductive Health\nMawson, Rebecca; The University of Sheffield, The Academic Unit of \nPrimary Medical Care\nHickey, Martha; The University of Melbourne, Obstetrics and \nGynaecology\nKeywords: Reproductive medicine, Pain\n \nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n\nConfidential: For Review Only\n1\n1 BMJ: Easily Missed: Endometriosis, an update \n2 Authors \n3 Louie Ye1,2 \n4 Job title: RANZCOG Trainee/Clinical Fellow  \n5 Lucy H R Whitaker3 \n6 Job title: NES/CSO Clinical Lecturer in Obstetrics & Gynaecology\n7 Rebecca L Mawson4\n8 Job title: GP & Academic Training Fellow\n9 Martha Hickey1,2 \n10 Job title: Professor of Obstetrics and Gynaecology \n11\n12 Affiliations\n13 1. The Royal Women’s Hospital, Melbourne, Victoria, Australia\n14 2. The Department of Obstetrics and Gynaecology, University of Melbourne and the \n15 Royal Women’s Hospital, Victoria, Australia\n16 3. MRC Centre for Reproductive Health, Queen's Medical Research Institute, University \n17 of Edinburgh, 49 Little France Crescent, EH16 4TJ\n18 4. The Academic Unit of Primary Medical Care, The University of Sheffield, Samuel Fox \n19 House, Sheffield, S5 7AU, UK.\n20\n21 Corresponding author: hickeym@unimelb.edu.au\n22\n23 Declarations \n24 The Corresponding Author has the right to grant on behalf of all authors and does grant on \n25 behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in \n26 all forms, formats and media (whether known now or created in the future), to i) publish, \n27 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into \n28 other languages, create adaptations, reprints, include within collections and create \n29 summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative \n30 work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) \n31 the inclusion of electronic links from the Contribution to third party material where-ever it \n32 may be located; and, vi) licence any third party to do any or all of the above.\n33\n34 We have read and understood the BMJ policy on declaration of interests and declare the \n35 following interests: None\n36\n37 Those named as authors have fulfilled all 4 ICMJE authorship criteria.\n38  \n39 Within our article, we use the terms ‘women’ and ‘women’s health’.  However, we \n40 acknowledge that it is necessary for all assigned female at birth, including those whose gender \n41 identity does not align with the sex they were assigned at birth, to access evidence-based care \n42 in order to maintain their gynaecological health and reproductive wellbeing.\n43\n44\n45\n46\n47\nPage 1 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n2\n48 Case presentation\n49 A 24-year-old woman presents to a new GP with several years of pain during sexual \n50 intercourse and increasingly painful periods affecting her mood, relationships and work. The \n51 pain persisted despite simple analgesia. She has had multiple contacts with healthcare \n52 professionals without a diagnosis or effective management. Her new GP suspects \n53 endometriosis. A transvaginal ultrasound (TVUS) and a three-month trial of combined oral \n54 contraceptive (COCP) is recommended. No pathology is identified on ultrasound. After three \n55 months, there was little improvement, and a gynaecology referral was offered.  Subsequent \n56 laparoscopy reveals superficial peritoneal endometriosis, and the patient opted for \n57 concurrent excisional surgery with insertion of a levonorgestrel-releasing intrauterine \n58 system, a choice reflecting her previous treatment experiences and current contraceptive \n59 requirements.\n60\n61\nWhat is it?\n62\n63 Endometriosis is defined as the “presence of endometrial-like tissue outside the uterus”(1). \n64 There are three sub-types: Superficial peritoneal, deep and ovarian (endometrioma cysts) \n65 though symptom severity and disease sub-type and extent are commonly discordant (1). \n66 Less frequently, endometriosis occurs in other anatomical locations such as the thorax or \n67 previous surgical incision sites (1). \n68\n69 Estimates of disease prevalence vary widely due to inconsistent presentation compounded \n70 by diagnostic challenges. In particular, the requirement of laparoscopy to make a diagnosis. \n71 The estimated population prevalence of endometriosis is 1 in 10 (2) but is higher in selected \n72 populations. For example in those with subfertility prevalence may be up to 50% (3). \n73\n74 Typical gynaecological presentations include painful periods and sub-fertility (1,4). Other \n75 symptoms include pain with sex and with defecation or urination which may be cyclical, and \n76 systemic manifestations such as fatigue (1,4,5). Sensitisation of central pathways may lead \n77 to chronic pain syndromes (6). Long-term consequences include impaired quality of life, \n78 anxiety, depression and self-harm(7,8). However, not all individuals with endometriosis \n79 have pain symptoms, particularly in the context of sub-fertility. \n80\n81 Factors contributing to sub-fertility may include reduced ovarian reserve, altered \n82 implantation and adhesion-related tubal occlusion, as well as decreased frequency of coitus \n83 due to associated pain(9). Endometriosis is commonly missed, leading to diagnostic delays. \n84 This article will discuss how the protean presenting symptoms and diagnostic criteria \n85 contribute to this delay. Endometriosis associated infertility will not be explicitly discussed \n86 because this diagnosis is commonly made during fertility investigations. \n87\n88\nWhy is it missed?\n89 The average diagnostic delay is seven years from the onset of symptoms to definitive \n90 diagnosis with variation between countries (10). In 2020, the UK diagnostic delay was eight \n91 years, which is unchanged in a decade (11). An important contributing factor is the delay \n92 between primary presentation and diagnostic testing (12–15). One third of patients had \n93 consulted their GP six or more times before referral, with 39% having two or more \n94 gynaecological referrals before a definitive diagnosis (14).\nPage 2 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n3\n95 Endometriosis is difficult to diagnose clinically as symptoms are both common and non-\n96 specific(15,16) and may be attributed to other conditions (17). For example, endometriosis \n97 may mimic or cause IBS, a common condition in primary care(17). The variable nature of \n98 presenting symptoms may lead them to be dismissed as functional or psychosomatic \n99 (12,13). Women consistently report difficulties in convincing doctors about the severity of \n100 their symptoms. This is compounded by clinicians dismissing or normalising symptoms such \n101 as painful periods (11,18). Affected women may also believe that their menstrual symptoms \n102 are normal (15). Diagnostic delay is even more common in adolescents(19), possibly due to \n103 a false belief that endometriosis takes time to cause symptoms after the onset of \n104 menarche(20). Cultural barriers may lead to reluctance or difficulty in reporting menstrual \n105 and sexual symptoms (11,18). The lack of reliable non-invasive tests likely contributes to \n106 delays in diagnosis and treatment(21,22). This is intensified by the variation and \n107 methodological quality of endometriosis guidelines leading to different diagnostic \n108 criteria(23).\n109 Why does it matter?\n110 Endometriosis may cause considerable suffering, distress and economic hardship for \n111 individuals(6,24). Diagnostic delays may have a significant impact socially and \n112 psychologically (25) and longer delay is associated with more advanced disease (26).  \n113 Chronic pain may impair quality of life, reduce productivity and workforce participation, and \n114 contribute to financial hardship (Figure 1)(6,7,11).  In the UK, the economic impact of \n115 endometriosis is estimated at around £8.2 billion per year, primarily due to absenteeism \n116 from work and healthcare costs (27). Direct treatment costs are comparable to conditions \n117 such as Type 2 diabetes or rheumatoid arthritis (27). \n118\n119 Around 30% of women with infertility have endometriosis (28), increasing to 50% in those \n120 with regular menstrual cycles and male partners normospermia(3). Delayed diagnosis may \n121 reduce the chance of pregnancy by 33% (29).  \n122\n123 With such profound consequences for individuals and society, \"reducing delayed diagnosis\" \n124 is a priority area for research (11,30).  Early diagnosis and prompt treatment might mitigate \n125 the psychosocial and economic burden associated with delayed management of \n126 endometriosis-related pain (12,15,29). However, it is not known whether earlier treatment \n127 affects the natural history of endometriosis or reduces the incidence of chronic pain \n128 syndromes\n129\n130\nHow is it diagnosed? \n131 There is a lack of consensus about how endometriosis should be diagnosed. In the UK, \n132 guidelines from the National Institute for Health and Care Excellence (NICE) and the \n133 European Society of Human Reproduction and Embryology (ESHRE) advise that laparoscopy \n134 is the gold standard diagnostic tool with histological confirmation (4,13). Limited access and \n135 cost of laparoscopy contribute to delayed diagnosis and others have argued that clinical and \n136 radiographic features are sufficient particularly for ovarian and deep sub-types (18). \n137 Improving diagnosis and non-invasive screening tools is a top 10 research priority for the UK \n138 (30).\n139\nPage 3 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n4\n140 Clinical features \n141 Initial suspicion and clinical diagnosis of endometriosis relies on a combination of clinical \n142 history, physical examinations, and imaging findings. Isolated pelvic examination in primary \n143 care is often uninformative (5). A normal pelvic exam or inability to perform an examination \n144 should not delay gynaecological referral(4).\n145 Management in primary care may include ruling out conditions such as pelvic infection, \n146 pregnancy, and inflammatory or irritable bowel disease. Previous presentations may also be \n147 informative. A study of primary care records found that women subsequently diagnosed \n148 with endometriosis were likely to have had multiple consults with menstrual pain within a \n149 12-month period, as well as gastrointestinal symptoms associated with menstruation (31). \n150 Managing complexity and uncertainty within the initial presentations of endometriosis \n151 symptoms underpins consultations in general practice(32).\n152 Investigations\n153 There are currently no biomarkers for endometriosis with adequate specificity or sensitivity, \n154 although this is an active area of research (21)(33). NICE and ESHRE guide against measuring \n155 Ca125 due to lack of sensitivity and specificity (4). NICE recommends transvaginal \n156 ultrasound (TVUS) as first-line imaging for suspected endometriosis (4). TVUS may exclude \n157 other potential conditions such as cysts and may identify ovarian endometriomas. \n158 Specialists in TVUS report a sensitivity of 79% and specificity of 94% for deep endometriosis \n159 and 3-D ultrasound may increase sensitivity to 87% (22,34). However, Access to specialist \n160 ultrasonography is limited in most settings. \n161\n162 Where TVUS is declined or inappropriate trans-abdominal ultrasound should be offered but \n163 has a lower sensitivity and specificity than TVUS (4). Ovarian and deep endometriosis may \n164 be visible on MRI (22). However, only around 17-44% of women with endometriosis present \n165 with endometriomas (35,36). \n166 Laparoscopy for direct visualisation of lesions remains gold standard diagnostic tool(4,13). \n167 However, access to laparoscopy contributes to the delay in diagnosis, is costly, invasive and \n168 carries surgical risks (37). In view of this, laparoscopy may not be required for diagnosis if \n169 imaging identifies endometriomas or deep disease. Similarly, laparoscopy may not be \n170 indicated for women with symptoms controlled by medical therapy if the patient is in \n171 agreement with a ‘working diagnosis’ of endometriosis(38).\n172\nHow is it managed? \n173 Management in primary and tertiary care should be holistic, addressing symptoms and \n174 offering psychological support, individualised to patient wishes and fertility priorities. In \n175 primary care, NICE recommends a 3-month trial of paracetamol or NSAIDs alone or \n176 combined with a COCP or continuous progestogen for pain suggestive of endometriosis(39). \n177 Patient Decision aids have been developed to support the choice of hormonal preparation \n178 (4). \n179\n180 Gynaecology referral is recommended when this initial management is ineffective or \n181 contraindicated. Women with severe or recurrent symptoms, endometriomas (>3cm), \n182 urinary tract/bowel involvement or infertility plus symptoms of endometriosis should also \n183 be referred to a specialist endometriosis centre if available(4). Medical treatments such as \nPage 4 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n5\n184 LNG-IUS and GnRHa may be used alone or in addition to surgery (pre- & post-operatively) to \n185 manage pain and reduce recurrence (40,41). \n186\n187 Laparoscopic excisional/ablative surgery is the mainstay of surgical treatment. Complex \n188 surgery for deep endometriosis involving the bowel, bladder or ureter is best managed \n189 within a specialist endometriosis centre(42). The risk of serious surgical complications \n190 depends on the extent, distribution and depth of disease, but is around 7% for surgical \n191 resection of deep endometriosis(42). Surgery may not be definitive and up to 50% report \n192 persistent symptoms at 5 years, indicating the importance of informed choice and follow-up \n193 care (43,44). Surgery has not been shown to improve fertility(39). A 2020 systematic review \n194 concluded that laparoscopic surgical management did not improve live birth rates and \n195 ovarian surgery may impair fertility (43). There are currently ongoing clinical trials examining \n196 the risks and benefits of sub-type specific surgery to improve pain, quality of life and fertility \n197 outcomes to inform evidenced-base and joint-decision making. \n198\n199\nReferences\n200 1. Saunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic \n201 prospects. Vol. 184, Cell. 2021. \n202 2. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North \n203 Am. 1997;24(2):235–58. \n204 3. Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. \n205 High prevalence of endometriosis in infertile women with normal ovulation and \n206 normospermic partners. Fertil Steril. 2009 Jul;92(1):68–74. \n207 4. National Institute for Health and Care Excellence - NICE. Endometriosis: diagnosis and \n208 management. 2017. \n209 5. RANZCOG. Endometriosis Clinical Practice Guideline Australia [Internet]. 2021 [cited \n210 2022 Apr 19]. Available from: \n211 https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s \n212 Health/Statement and guidelines/Clinical - Gynaecology/Endometriosis-clinical-\n213 practice-guideline.pdf?ext=.pdf\n214 6. Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: A \n215 review of pelvic and central nervous system mechanisms. Best Pract Res Clin Obstet \n216 Gynaecol. 2018 Aug 1;51:53–67. \n217 7. Estes SJ, Huisingh CE, Chiuve SE, Petruski-Ivleva N, Missmer SA. Depression, Anxiety, \n218 and Self-Directed Violence in Women With Endometriosis: A Retrospective Matched-\n219 Cohort Study. Am J Epidemiol. 2021;190(5):843–52. \n220 8. Nnoaham KE, Hummelshoj L, Webster P, D’Hooghe T, De Cicco Nardone F, De Cicco \n221 Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a \n222 multicenter study across ten countries. Fertil Steril. 2011;96(2). \n223 9. Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of \n224 pathophysiological mechanisms and treatment options. Acta Obstet Gynecol Scand. \n225 2017 Jun 1;96(6):659–67. \n226 10. Zondervan KT, Becker CM, Missmer SA. Endometriosis. Longo DL, editor. N Engl J \n227 Med. 2020 Mar 26;382(13):1244–56. \n228 11. APPG. APPG on Endometriosis Inquiry Report 2020. Endometriosis in the UK: time for \n229 change (October 2020) - Women’s health - Patient Safety Learning - the hub. 2020. \nPage 5 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n6\n230 12. Ballard K, Lowton K, Wright J. What’s the delay? A qualitative study of women’s \n231 experiences of reaching a diagnosis of endometriosis. Fertil Steril. 2006 \n232 Nov;86(5):1296–301. \n233 13. Dunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, et al. \n234 ESHRE guideline: management of women with endometriosis. Hum Reprod. \n235 2014;29(3):400–12. \n236 14. Pugsley Z, Ballard K. Management of endometriosis in general practice: the pathway \n237 to diagnosis. Br J Gen Pract. 2007 Jun;57(539):470. \n238 15. Staal AHJ, Van Der Zanden M, Nap AW. Diagnostic Delay of Endometriosis in the \n239 Netherlands. Gynecol Obstet Invest. 2016 Jul 1;81(4):321–4. \n240 16. Abbas S, Ihle P, Köster I, Schubert I. Prevalence and incidence of diagnosed \n241 endometriosis and risk of endometriosis in patients with endometriosis-related \n242 symptoms: findings from a statutory health insurance-based cohort in Germany. Eur J \n243 Obstet Gynecol Reprod Biol. 2012;160(1):79–83. \n244 17. Ballard KD, Seaman HE, De Vries CS, Wright JT. Can symptomatology help in the \n245 diagnosis of endometriosis? Findings from a national case-control study--Part 1. \n246 BJOG. 2008 Oct;115(11):1382–91. \n247 18. Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al. Clinical \n248 diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019 Apr \n249 1;220(4):354.e1-354.e12. \n250 19. Soliman AM, Fuldeore M, Snabes MC. Factors Associated with Time to Endometriosis \n251 Diagnosis in the United States. J Womens Health (Larchmt). 2017 Jul 1;26(7):788–97. \n252 20. Saridotan E. Endometriosis in teenagers. Women’s Heal. 2015;11(5):705–9. \n253 21. Nisenblat V, Bossuyt PMM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, et al. Blood \n254 biomarkers for the non-invasive diagnosis of endometriosis. Cochrane database Syst \n255 Rev. 2016 May 1;2016(5). \n256 22. Nisenblat V, Bossuyt PMM, Farquhar C, Johnson N, Hull ML. Imaging modalities for \n257 the non-invasive diagnosis of endometriosis. Cochrane database Syst Rev. 2016 Feb \n258 26;2(2). \n259 23. Hirsch M, Begum MR, Paniz, Barker C, Davis CJ, Duffy JMN. Diagnosis and \n260 management of endometriosis: a systematic review of international and national \n261 guidelines. BJOG An Int J Obstet Gynaecol. 2018 Apr 1;125(5):556–64. \n262 24. Fuldeore MJ, Soliman AM. Prevalence and Symptomatic Burden of Diagnosed \n263 Endometriosis in the United States: National Estimates from a Cross-Sectional Survey \n264 of 59,411 Women. Gynecol Obstet Invest. 2017 Sep 1;82(5):453–61. \n265 25. Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, et al. The social and \n266 psychological impact of endometriosis on women’s lives: a critical narrative review. \n267 Hum Reprod Update. 2013 Nov;19(6):625–39. \n268 26. Matsuzaki S, Canis M, Pouly JL, Rabischong B, Botchorishvili R, Mage G. Relationship \n269 between delay of surgical diagnosis and severity of disease in patients with \n270 symptomatic deep infiltrating endometriosis. Fertil Steril. 2006 Nov 1;86(5):1314–6. \n271 27. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The \n272 burden of endometriosis: costs and quality of life of women with endometriosis and \n273 treated in referral centres. Hum Reprod. 2012;27(5):1292–9. \n274 28. Gruppo italiano per lo studio dell’endometriosi. Endometriosis: Prevalence and \nPage 6 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n7\n275 anatomical distribution of endometriosis in women with selected gynaecological \n276 conditions: Results from a multicentric italian study. Hum Reprod. 1994;9(6). \n277 29. Moss KM, Doust J, Homer H, Rowlands IJ, Hockey R, Mishra GD. Delayed diagnosis of \n278 endometriosis disadvantages women in ART: a retrospective population linked data \n279 study. Hum Reprod. 2021 Nov 18;36(12):3074–82. \n280 30. Horne AW, Saunders PTK, Abokhrais IM, Hogg L. Top ten endometriosis research \n281 priorities in the UK and Ireland. Lancet (London, England). 2017 Jun \n282 3;389(10085):2191–2. \n283 31. Burton C, Iversen L, Bhattacharya S, Ayansina D, Saraswat L, Sleeman D. Pointers to \n284 earlier diagnosis of endometriosis: a nested case-control study using primary care \n285 electronic health records. Br J Gen Pract. 2017 Dec 1;67(665):e816–23. \n286 32. Dixon S, McNiven A, Talbot A, Hinton L. Navigating possible endometriosis in primary \n287 care: a qualitative study of GP perspectives. Br J Gen Pract. 2021 Sep 1;71(710):e668–\n288 76. \n289 33. Tian Z, Chang XH, Zhao Y, Zhu HL. Current biomarkers for the detection of \n290 endometriosis. Chin Med J (Engl). 2020;133(19):2346–52. \n291 34. Guerriero S, Saba L, Ajossa S, Peddes C, Angiolucci M, Perniciano M, et al. Three-\n292 dimensional ultrasonography in the diagnosis of deep endometriosis. Hum Reprod. \n293 2014;29(6). \n294 35. Jenkins S, Olive D. Endometriosis: pathogenetic implications of the anatomic \n295 distribution. Obstet Gynecol. 1986;67(3):335–8. \n296 36. Redwine DB. Ovarian endometriosis: A marker for more extensive pelvic and \n297 intestinal disease. Fertil Steril. 1999;72(2). \n298 37. Royal Colleges of Obstetrics and Gynaecology. Diagnostic Laparoscopy (Consent \n299 Advice No. 2) [Internet]. [cited 2022 Apr 25]. Available from: \n300 https://www.rcog.org.uk/guidance/browse-all-guidance/consent-advice/diagnostic-\n301 laparoscopy-consent-advice-no-2/\n302 38. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and \n303 management of endometriosis. Nat Rev Endocrinol 2019 1511. 2019 Sep \n304 5;15(11):666–82. \n305 39. Kalaitzopoulos DR, Samartzis N, Kolovos GN, Mareti E, Samartzis EP, Eberhard M, et \n306 al. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC \n307 Womens Health. 2021 Dec 1;21(1). \n308 40. Chen I, Veth VB, Choudhry AJ, Murji A, Zakhari A, Black AY, et al. Pre- and postsurgical \n309 medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2020 Nov \n310 18;2020(12). \n311 41. Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis \n312 recurrence following post-operative hormonal suppression: a systematic review and \n313 meta-analysis. Hum Reprod Update. 2021 Jan 4;27(1):96–107. \n314 42. Byrne D, Curnow T, Smith P, Cutner A, Saridogan E, Clark TJ. Laparoscopic excision of \n315 deep rectovaginal endometriosis in BSGE endometriosis centres: a multicentre \n316 prospective cohort study. BMJ Open. 2018 Apr 1;8(4):e018924. \n317 43. Bafort C, Beebeejaun Y, Tomassetti C, Bosteels J, Duffy JMN. Laparoscopic surgery for \n318 endometriosis. Cochrane database Syst Rev. 2020 Oct 23;10(10). \n319 44. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. \nPage 7 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n8\n320 2009;15(4):441–61. \n321 45. Rowlands IJ, Abbott JA, Montgomery GW, Hockey R, Rogers P, Mishra GD. Prevalence \n322 and incidence of endometriosis in Australian women: a data linkage cohort study. \n323 BJOG An Int J Obstet Gynaecol. 2021 Mar 1;128(4):657–65. \n324\nPage 8 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n9\n325\n326\nHow common is it\nA US cross-sectional survey estimated the prevalence of diagnosed endometriosis at \n6.1%(24), with a predominant symptom burden in those aged 18-29. This was \ncorroborated by an Australian study reporting that 6.3% of women aged 40-44 years have \nconfirmed endometriosis (45). \nMore prevalent in certain patient groups (2)\n Asymptomatic women - 2 to 11%\n Women with infertility  - 5 to 50%\n Women hospitalised for pelvic pain - 5 to 21% \n Women with chronic pelvic pain - 50%–75% \n327\nWhat you need to know \n1. No non-invasive diagnostic tools are available to identify endometriosis, \nlaparoscopic biopsy of endometriotic lesions remains the gold standard for \ndiagnosis \n2. Consider endometriosis in women of reproductive age with abdomino-pelvic pain \nassociated with menstruation, sexual intercourse, urination, defecation, and \ninfertility.\n3. Pain from suspected endometriosis can be managed in primary care with initial \ntreatment with hormonal contraceptive methods including LNG-IUS combined \nwith analgesia without laparoscopic confirmation\n328\nHow patients were involved in the creation of this article\nWe asked two people living with endometriosis in the UK for comments on an early draft \nof this paper. In response to their comments, we revised the case to highlight the fact it \noften takes several years and many visits for endometriosis to be suspected & \ninvestigated. We also sought to highlight the impact of endometriosis on quality of life \nand the recurrence/ongoing impact after surgical excision.\n329\nEducation into practice\n How do you communicate with your patients about their menstrual symptoms?\n How do you make a provisional diagnosis of endometriosis?\n What are the initial treatments you can offer and how would you adapt these for \ndifferent patients?\n330\n331 Figure 1\nPage 9 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60\n\nConfidential: For Review Only\n10\n332\n333\n334 Reproduced with copyright permission from Horne & Saunders 2019 (28). \n335\nPage 10 of 10\nhttps://mc.manuscriptcentral.com/bmj\nBMJ\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35\n36\n37\n38\n39\n40\n41\n42\n43\n44\n45\n46\n47\n48\n49\n50\n51\n52\n53\n54\n55\n56\n57\n58\n59\n60","source_license":"CC0","license_restricted":false}